Alzamend Neuro Beheer

Beheer criteriumcontroles 4/4

De CEO Alzamend Neuro is Stephan Jackman, benoemd in Nov2018, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 443.62K, bestaande uit 78.9% salaris en 21.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.007% van de aandelen van het bedrijf, ter waarde $ 396.91. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 3.4 jaar.

Belangrijke informatie

Stephan Jackman

Algemeen directeur

US$443.6k

Totale compensatie

Percentage CEO-salaris	78.9%
Dienstverband CEO	6yrs
Eigendom CEO	0.007%
Management gemiddelde ambtstermijn	5.5yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

Analyse CEO-vergoeding

Hoe is Stephan Jackman's beloning veranderd ten opzichte van Alzamend Neuro's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	-US$7m
Apr 30 2024	US$444k	US$350k	-US$10m
Jan 31 2024	n/a	n/a	-US$12m
Oct 31 2023	n/a	n/a	-US$15m
Jul 31 2023	n/a	n/a	-US$15m
Apr 30 2023	US$2m	US$300k	-US$15m
Jan 31 2023	n/a	n/a	-US$15m
Oct 31 2022	n/a	n/a	-US$13m
Jul 31 2022	n/a	n/a	-US$13m
Apr 30 2022	US$473k	US$303k	-US$12m
Jan 31 2022	n/a	n/a	-US$10m
Oct 31 2021	n/a	n/a	-US$8m
Jul 31 2021	n/a	n/a	-US$6m
Apr 30 2021	US$225k	US$225k	-US$5m
Jan 31 2021	n/a	n/a	-US$5m
Oct 31 2020	n/a	n/a	-US$5m
Jul 31 2020	n/a	n/a	-US$5m
Apr 30 2020	US$2m	US$188k	-US$4m
Jan 31 2020	n/a	n/a	-US$4m
Oct 31 2019	n/a	n/a	-US$4m
Jul 31 2019	n/a	n/a	-US$4m
Apr 30 2019	US$3m	US$50k	-US$5m

Compensatie versus markt: De totale vergoeding ($USD 443.62K ) Stephan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Stephan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Stephan Jackman (48 yo)

6yrs

Tenure

US$443,617

Compensatie

Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and has been its Director since September 2020. Mr. Jackman has experience in administration, business a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephan Jackman	CEO & Director	6yrs	US$443.62k	0.0068% $ 396.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	0.37% $ 21.9k
David Katzoff	Chief Financial Officer	2.3yrs	US$150.00k	0.012% $ 707.6
Henry C. Nisser	Executive VP	5.5yrs	US$50.00k	0% $ 0
Kenneth Cragun	Senior Vice President of Finance	3.4yrs	geen gegevens	0% $ 0

5.5yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALZN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephan Jackman	CEO & Director	4.2yrs	US$443.62k	0.0068% $ 396.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	0.37% $ 21.9k
Henry C. Nisser	Executive VP	4.2yrs	US$50.00k	0% $ 0
William Horne	Chairman of the Board	8.4yrs	US$50.00k	0.15% $ 8.7k
Mark Gustafson	Independent Director	3.4yrs	US$25.00k	0.0089% $ 524.1
Lynne McGrath	Independent Director	3.4yrs	US$25.00k	0.011% $ 654.9
Thomas Wisniewski	Member of Scientific Advisory Board	5.3yrs	geen gegevens	geen gegevens
Eric McDade	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Oram	Independent Director	3.4yrs	US$25.00k	0.015% $ 872.4
Andrew Woo	Independent Director	3.4yrs	US$25.00k	0.015% $ 872.4
Terri Hunter	Member of Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALZN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Alzamend Neuro Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

High number of new and inexperienced directors

Alzamend Neuro, Inc. Announces CFO Changes

No independent directors

Recent updates

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro closes $14.4M IPO

Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd